Paving the Path to a Healthier Future
Identifying Molecules That Regulate Intrinsic Biochemical Mechanisms for Protection Against Oxidative Damage
About Prolindox
Our Mission
Therapeutic Targets
Therapeutic Targets
Prolindox, a company founded in 2020, embarked with the mission of finding ways to activate/upregulate the intrinsic biochemical mechanisms, conserved, and refined throughout evolution, that cells employ to protect against oxidative damage. This approach to protect cells against oxidative damage evolved from Dr. Weissbach’s initial disc
Prolindox, a company founded in 2020, embarked with the mission of finding ways to activate/upregulate the intrinsic biochemical mechanisms, conserved, and refined throughout evolution, that cells employ to protect against oxidative damage. This approach to protect cells against oxidative damage evolved from Dr. Weissbach’s initial discovery of the methionine sulfoxide reductase (MSRA) system, more than 40 years ago, that repaired damage to proteins, due to oxidation of protein-bound methionine. In addition to studies on the MSR system, Prolindox has small molecules that upregulate other important cellular protective mechanisms against oxidative damage. These cellular processes, protect against aberrant nucleic acid, protein and lipid oxidation caused by excessive reactive oxygen species (ROS). Fundamental insights into these anti-oxidative pathways, essential for life to thrive in an oxygen-laden atmosphere, make it possible to modulate these pathways to develop therapies for diseases involving oxidative damage.
Therapeutic Targets
Therapeutic Targets
Therapeutic Targets
- Oxidative damage has been linked to the etiology of a wide range of diseases including age related cardiovascular, eye and neurodegenerative diseases. It also plays a role in cancer and many genetic diseases. The initial targets for these small molecule drugs that induce cellular protection against oxidative damage are:
- 1) Retinitis pigme
- Oxidative damage has been linked to the etiology of a wide range of diseases including age related cardiovascular, eye and neurodegenerative diseases. It also plays a role in cancer and many genetic diseases. The initial targets for these small molecule drugs that induce cellular protection against oxidative damage are:
- 1) Retinitis pigmentosa, a genetic eye disease and age-related eye diseases such as macular degeneration and glaucoma.
- 2) Cardiovascular diseases with the goal of protecting the heart and other organs against ischemia/reperfusion damage, as occurs in heart attacks and stroke.
- 3) A gene therapy approach to increase the level of MSR enzymes in tissues is being developed, since recent findings have shown that specific methionine oxidation in proteins may play a role in disease pathogenesis.
- Lead compound and initial focus
- Prolindox has promising results using 3 drugs that protect cells against oxidative damage. One of the drugs is effective in slowing blindness in an animal model of the genetic disease, retinitis pigmentosa.
- Prolindox has obtained Orphan Drug Designation from the FDA for this lead compound to treat retinitis pigmentosa
Our Team
Therapeutic Targets
Our Team
Our team consists of highly skilled professionals with years of experience in their respective fields.
Founder and Scientific Adviser: Herbert Weissbach, Ph.D., Professor Emeritus, Florida Atlantic University. Dr. Weissbach is recognized as a leader in the broad field of oxidative damage. He is a Member of the National Academy of Scienc
Our team consists of highly skilled professionals with years of experience in their respective fields.
Founder and Scientific Adviser: Herbert Weissbach, Ph.D., Professor Emeritus, Florida Atlantic University. Dr. Weissbach is recognized as a leader in the broad field of oxidative damage. He is a Member of the National Academy of Sciences, American Academy of Microbiology and National Academy of Inventors. He is a former VP of Research at Hoffmann-La Roche and co-founder and Director of the Roche Institute of Molecular Biology (RIMB). After retiring from Roche, he founded and was Director of the Center for Molecular Biology and Biotechnology at Florida Atlantic University. Dr. Weissbach has authored over 460 scientific articles and book chapters.
Subramanian Iyer, Ph.D., Chief Executive Officer, Affiliate Member of the Center for Molecular Biology and Biotechnology at Florida Atlantic Univ.Serial entrepreneur with 20 + year leadership positions. Cofounder and CSO of ProdIgY Biotech, a company that has successfully completed its preclinical research and is ready for Series A funding to embark on clinical trials. He has several publications in top tier journals and over a dozen patents.
Donald Fishbein: Chief Business Officer. A highly successful entrepreneur, providing customized business advisory solutions for emerging ophthalmology companies, including commercial development. Successfully created strategic roadmap for all aspects of initial product launch.
Adrian Rabinowicz: M.D. Medical Advisor. Highly accomplished executive with 23+ years of success leading medical product development, US and ex-US regulatory submissions, and product launches for biotech / pharmaceutical companies. Directed and organized all clinical development activities from human proof of concept through Phase 4 programs.
Lawrence Weissbach, Ph.D., Scientific Advisor. Extensive research and pharmaceutical operational background covering cancer translational research, management of preclinical research contracts and academic/industry alliances, outsourced CRO studies, and consulting. Previously an Assistant Professor/Principal Investigator at Massachusetts General Hospital, focusing on cancer biology, inflammation, and drug discovery.
Contact Us
Questions or Comments?
If you would like to learn more about Prolindox please email us at iyersubra10@gmail.com or call the number listed below.
Prolindox
Hours
